Handelsavisen
prelaunch
Companies Healthcare ZYUS.V
ZY
ZYUS.V TSX Venture Biotechnology & Medical Research

Zyus.V

$0,00
Open in Charts → Attach watcher ⌖
CAD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
38,6M CAD
P/E
EV / Rev
Div yield
Op margin
-7 274,8 %
ROE
632,6 %
Net margin
-7 028,1 %
Debt / equity
-2,28
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

ZYUS.V is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and commercialization of diagnostic solutions.

Business. ZYUS.V is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and commercialization of diagnostic solutions.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
632,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ZYUS.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ZYUS.V. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ZYUS.V is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and commercialization of diagnostic solutions.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    ZYUS.V operates with a negative equity position of CAD -5,344,000 and a debt-to-equity ratio of -2.28, indicating a highly leveraged capital structure. The company's liquidity is constrained, as evidenced by a current ratio of 0.19, suggesting limited short-term liquidity to cover immediate obligations. The valuation snapshot reveals a market cap of CAD 38,613,772.89 and an enterprise value to revenue ratio of 105.56, which is significantly higher than typical for the industry, reflecting a high valuation relative to its current revenue base.

    ZYUS.V's profitability is challenged, with a net loss of CAD -33,805,000 and an operating loss of CAD -34,992,000, indicating a substantial decline in profitability. The return on equity of 6.3258% is positive but modest, while the return on assets is negative at -2.3039%, suggesting inefficient use of assets to generate profit. These metrics fall below the industry norms, highlighting the company's struggle to maintain profitability in a competitive market.

    The company's revenue is concentrated in a single segment, with no disclosed geographic diversification, which increases its exposure to market-specific risks. This lack of diversification could lead to volatility in revenue and earnings, particularly if the primary market experiences downturns or regulatory changes.

    ZYUS.V's growth trajectory is uncertain, with a net loss in the latest reporting period and no indication of a turnaround in the near term. The company's operating cash flow is negative at CAD -9,876,000, and free cash flow is also negative at CAD -30,890,000, indicating a lack of cash generation to support operations or growth initiatives. These financial constraints may limit the company's ability to invest in research and development or expand its market presence.

    The risk assessment for ZYUS.V indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, suggesting potential difficulties in meeting short-term obligations. The dilution risk is low, but the company's negative equity and high debt levels could lead to further dilution if additional financing is required.

    Recent events, including the latest financial results and analyst estimates, indicate a lack of confidence in the company's future performance. The mean recommendation from analysts is 2.00, which is a "Hold" rating, with no strong buy or sell recommendations. The last actual EPS was -0.47 CAD, significantly below the mean estimate of -0.22 CAD, indicating a negative earnings surprise.

    Key takeaways
    • ZYUS.V is a biotechnology company with a negative equity position and high leverage, indicating a challenging capital structure.
    • The company's profitability is severely impacted by a large net loss and negative operating income, which are below industry norms.
    • Revenue concentration in a single segment and lack of geographic diversification increase exposure to market-specific risks.
    • The company's growth trajectory is uncertain, with negative operating and free cash flows limiting its ability to invest in growth initiatives.
    • Analysts have a neutral outlook on the company, with a "Hold" rating and a negative earnings surprise in the latest reporting period.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,00
    Market cap
    $38.6M
    Enterprise value
    $50.8M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$5.3M
    Net cash
    -$12.2M
    Current ratio
    0.2
    Debt / equity
    -2.3
    ROA
    -2.3%
    ROE
    6.3%
    Cash conversion
    29.0%
    CapEx / revenue
    -9.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,22
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-08 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,22
    Revenueno estimateno estimate448,000 CAD
    Operating incomeno estimateno estimateno estimate
    Full-year consensus mean (period as reported by source) · consensus in CAD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    EPS surprise
    −113,6 %
    reported vs consensus · miss
    Revenue surprise
    +7,4 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-7 274,8 %Bottom quartile
    Net Margin-7 028,1 %Bottom quartile
    ROE632,6 %Best in class
    Capex / Rev-9,6 %Below median
    D/E-2,28Best in class
    Cash Conv0,29Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • ZYUS.V Market data — financials · 2026-05-30
    • ZYUS Life Sciences Corp Market data — analyst estimates · 2026-05-30

    Ownership & reference

    Leadership

    • Brent ZettlPresident, Chief Executive Officer
    • Charlotte Moore HepburnChairman of the Board, Chief Executive Officer

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ZYUS.VCanonical
    TSX Venture · CAD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage